NeuroBo Pharmaceuticals (NRBO) Stock Price, News & Analysis

Company Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.63 to $0.65
• 50-Day Range: $0.60 to $0.74
• 52-Week Range: $2.08 to $4.41
• Volume: 23,790 shs
• Average Volume: 39,605 shs
• Market Capitalization: $5.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRBO Stock Analysis - Frequently Asked Questions

How have NRBO shares performed this year?

NeuroBo Pharmaceuticals' stock was trading at $2.03 at the beginning of the year. Since then, NRBO stock has decreased by 68.8% and is now trading at $0.6340.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) posted its earnings results on Thursday, November, 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.27.

When did NeuroBo Pharmaceuticals' stock split?

NeuroBo Pharmaceuticals's stock reverse split before market open on Thursday, December 21st 2023.The 1-8 reverse split was announced on Thursday, December 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroBo Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), GE Aerospace (GE) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 8/28/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Banking
• Current Symbol: NASDAQ:NRBO
• CIK: 1638287
• Web: www.neurobopharma.com
• Phone: (857) 702-9600
• Fax: 734-293-0444
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -189.12%
• Return on Assets: -122.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 8,616,000
• Free Float: 8,526,000
• Market Cap: $5.46 million
• Optionable: Not Optionable
• Beta: -0.26